Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 16/20 | 0.73 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13663644 | 0.92 | AR (0.69) | ARP2RX7KDM4EDGAT2PTGER1 | |
| SCHEMBL4300521 | 0.89 | AR (0.79) | ARP2RX7 | |
| Trifluoroacetic Acid SCHEMBL4236341 | 0.88 | AR (0.62) | ARP2RX7KDM4EDGAT2 | |
| SCHEMBL13663636 | 0.87 | AR (0.69) | ARP2RX7 | |
| SCHEMBL4237479 | 0.87 | AR (0.77) | AR | |
| SCHEMBL4233559 | 0.86 | AR (0.73) | AR | |
| SCHEMBL4296438 | 0.85 | AR (0.71) | ARP2RX7KDM4E | |
| SCHEMBL4239054 | 0.85 | AR (1.00) | AR | |
| SCHEMBL4241335 | 0.84 | AR (1.00) | AR | |
| SCHEMBL4232524 | 0.84 | AR (0.73) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | CBR3, CBR1, NOX5 | AR 622/4885P2RX7 681/4885KDM4E 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.